All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Nathan Fowler, MD Anderson Cancer Center, Houston, US, who discussed the non-chemotherapy approaches to treating follicular lymphoma.
Can we avoid chemotherapy entirely in follicular lymphoma?
Treatment for follicular lymphoma has been improving over recent years. The addition of rituximab, an anti-CD20 antibody, to the clinician's arsenal has been a real game changer in the field. Nathan Fowler describes its mode of action and the role it plays in modern treatment strategies.
Fowler discusses the different courses the disease can take and how therapy can be tailored to suit an individual's needs. The current treatment standards and the response rates achieved with these agents are examined.
Lenalidomide, an immunomodulatory drug, in combination with rituximab was investigated in comparison to three different chemotherapy regimes in the RELEVANCE trial, and Fowler details the outcomes of this study. The differing adverse events experienced by patients following these therapies are listed. He goes on to say how this result has influenced his clinical practice and how the presence of high-risk factors impacts treatment decision making.
Nathan Fowler rounds off his talk by introducing other non-chemotherapy options, such as obinutuzumab, Pi3 kinase inhibitors, tazemetostat, and chimeric antigen receptor (CAR) T cells.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox